SCHEDULE 13G/A: Meteora Capital and Vik Mittal Disclose 6.13% Stake in NKGen Biotech
Beneficial Ownership Disclosure
Meteora Capital, LLC and its managing member Vik Mittal have disclosed a 6.13% beneficial ownership stake in NKGen Biotech, Inc., held in the ordinary course of business.
Summary
- Meteora Capital, LLC and Vik Mittal, as Reporting Persons, collectively reported beneficial ownership of 2,755,935 shares of NKGen Biotech, Inc. Common Stock.
- This ownership represents 6.13% of the total outstanding Common Stock of NKGen Biotech, Inc.
- Both Meteora Capital, LLC and Vik Mittal share voting power and dispositive power over all 2,755,935 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, indicating no immediate positive or negative implications for the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement |
| 05/15/2025 | Date of filing of this Schedule 13G |
Keywords
NKGen Biotech, Meteora Capital, Vik Mittal, Schedule 13G, SEC filing, beneficial ownership, common stock, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.